Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Verve Therapeutics (VERV) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 50.70%. A quarter ago, it was expected that this biotechnology firm would post a loss of $0.72 per share when it actually produced a loss of $0.58, delivering a surprise of 19.44%.Over the last four quarters, the compan ...

Core Viewpoint - Karyopharm Therapeutics reported a quarterly loss of $2.77 per share, significantly better than the Zacks Consensus Estimate of a loss of $4.21, marking an earnings surprise of 34.20% [1] Financial Performance - The company posted revenues of $30.02 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 16.18%, compared to $33.13 million in the same quarter last year [2] - Over the last four quarters, Karyopharm has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Karyopharm shares have declined approximately 40.7% since the beginning of the year, while the S&P 500 has decreased by 3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$3.90 on revenues of $39.29 million, and for the current fiscal year, it is -$14.05 on revenues of $150.29 million [7] Industry Outlook - The Medical - Drugs industry, to which Karyopharm belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Company Performance - FibroGen reported a quarterly loss of $0.16 per share, significantly worse than the Zacks Consensus Estimate of $0.03, representing an earnings surprise of -633.33% [1] - The company posted revenues of $2.74 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 71.19%, but down from $55.9 million in the same quarter last year [2] - Over the last four quarters, FibroGen has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Movement and Outlook - FibroGen shares have declined approximately 41.8% since the beginning of the year, compared to a -3.8% decline in the S&P 500 [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.09 for the coming quarter and -$0.60 for the current fiscal year [4][7] - The current estimate revisions trend for FibroGen is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which FibroGen belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact FibroGen's stock performance [5]

Company Performance - Aurinia Pharmaceuticals reported quarterly earnings of $0.16 per share, exceeding the Zacks Consensus Estimate of $0.08 per share, compared to a loss of $0.03 per share a year ago, representing an earnings surprise of 100% [1] - The company posted revenues of $62.47 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.63%, and showing an increase from year-ago revenues of $50.3 million [2] - Over the last four quarters, Aurinia has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance and Outlook - Aurinia shares have declined approximately 10.9% since the beginning of the year, while the S&P 500 has decreased by 3.8% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $64.76 million, and for the current fiscal year, it is $0.44 on revenues of $258.28 million [7] Industry Context - The Medical - Drugs industry, to which Aurinia belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Performance - Crinetics Pharmaceuticals reported a quarterly loss of $1.04 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.99, and compared to a loss of $0.93 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $0.36 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 261%, but this was a decrease from year-ago revenues of $0.64 million [2] - Over the last four quarters, Crinetics has only surpassed consensus EPS estimates once, indicating inconsistent performance [2] Stock Movement and Outlook - Crinetics Pharmaceuticals shares have declined approximately 38.6% since the beginning of the year, significantly underperforming the S&P 500, which declined by only 4.3% [3] - The company's earnings outlook is uncertain, with current consensus EPS estimates for the upcoming quarter at -$1.10 on revenues of $2.6 million, and for the current fiscal year at -$4.33 on revenues of $5.63 million [7] Industry Context - The Medical - Drugs industry, to which Crinetics belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a relatively strong industry performance [8] - The performance of Crinetics may be influenced by the overall outlook for the industry, as empirical research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 200%. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.08 per share when it actually produced a loss of $0.10, delivering a surprise of -25%.Over the las ...

Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.29%. A quarter ago, it was expected that this company would post a loss of $0.07 per share when it actually produced a loss of $0.03, delivering a surprise of 57.14%.Over the last four quarters, the company has surpasse ...

分组1 - ElectroCore, Inc. reported a quarterly loss of $0.47 per share, better than the Zacks Consensus Estimate of a loss of $0.56, and an improvement from a loss of $0.53 per share a year ago, resulting in an earnings surprise of 16.07% [1] - The company posted revenues of $6.72 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.12%, but showing an increase from $5.44 million in the same quarter last year [2] - ElectroCore shares have declined approximately 57% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.42 on revenues of $7.62 million, and for the current fiscal year, it is -$1.36 on revenues of $31.44 million [7] - The Zacks Industry Rank for Medical - Drugs is in the top 26% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]

Xencor (XNCR) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $1.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -4.76%. A quarter ago, it was expected that this biotech developing antibodies for severe autoimmune/allergic diseases and cancer would post a loss of $0.83 per share when it actually produced a loss of $0.62, delivering a surprise ...